SLV213 Treatment in Ambulatory COVID-19 Patients

Inclusion Criteria: 1. Agree to participate in the trial by signing the IRB approved Informed Consent 2. Age ≥ 18 years of age 3. Positive diagnosis for COVID-19 by SARS-CoV-2 PCR by nasopharyngeal swab within the past 3 days 4. Two or more COVID-19 symptoms (at least one of which must be Respiratory) rated Mild or Moderate on the COVID-19 adapted FLU-PRO Plus scale 5. SpO2 ≥ 94% 6. Ambulatory (not hospitalized) at the time of enrollment 7. Normal (or stable if abnormal per comorbidity) baseline ECG 8. Men of child-bearing potential must use birth control with heterosexual partner(s) (abstinence or condoms) 9. Women of child-bearing potential must meet all the following criteria: * Use of birth control (abstinence, oral contraceptives, condoms, or intrauterine device) * Test negative for β-subunit of HCG Exclusion Criteria: 1. Pregnant or lactating 2. Treatment with COVID-19 antiviral such as remdesivir or SARS-CoV-2 antibodies 3. At increased risk of developing more severe COVID-19 disease (at least one of the following): 1. Age ≥60 years 2. Presence of pulmonary disease, specifically moderate or severe persistent asthma, chronic obstructive pulmonary disease, pulmonary hypertension, emphysema 3. Diabetes mellitus (type 1 or 2), requiring oral medication or insulin for treatment 4. Cardiovascular disease, including Hypertension, requiring at least 1 oral medication for treatment; congestive heart failure; coronary artery disease; cardiomyopathy; pulmonary hypertension 5. Body mass index ≥30 6. Chronic renal disease (but not on dialysis) 7. Sickle cell disease or trait 4. Severe or Critical COVID-19, as indicated by respiratory distress or shortness of breath at rest; Resp Rate ≥30/min; Heart rate ≥125/min; SpO2 ≤ 93% on room air or PaO2/FiO2 ≤ 300 if on supplemental O2 5. Positive HIV or positive Hepatitis Panel 6. Treatment with any medications known to be strongly metabolized by CYP3A4 or CYP2D6